Bright Minds Biosciences Inc. (DRUG) stock
DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30
$20.76+0.25 (+1.22%)
Close on Nov 18, 2026Market cap $158.52MP/E –Yield –
Bright Minds Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was C$11.08M, up 839.4% from the year before. The highest annual figure on record is C$12.18M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | C$11.08M | +839.4% |
| FY2024 | Sep 30, 2024 | C$1.18M | -76.4% |
| FY2023 | Sep 30, 2023 | C$5.00M | -59.0% |
| FY2022 | Sep 30, 2022 | C$12.18M | +92.9% |
| FY2021 | Sep 30, 2021 | C$6.31M | +1679.3% |
| FY2020 | Sep 30, 2020 | C$354.85K | – |
See a number that looks wrong?